Comparison of PI vs PI
ANDES Study: DRV/r + 3TC vs DRV/r + 3TC/TDF
Original article : Figueroa MI, CROI 2018, Abs. 489
Last update :
11/05/2018
Dr Anton Pozniak
Chelsea and Westminster Hospital
London, UK
- DRV/r + 3TC dual therapy was virologically non inferior to a standard therapy of DRV/r + 3TC/TDF in naïve patients
- Similar virologic response of the 2 regimens in patients with HIV
RNA > 100 000 c/mL at enrolment
- Only 1 case of virologic failure (DRV/r + 3TC/TDF) with no emergence of resistance
- Incidence of gastro-intestinal adverse events higher in triple therapy group
- Lipid elevations higher in the DRV/r + 3TC group, significantly higher than in DRV/r + 3TC/TDF group for total cholesterol
Design
*Randomisation was stratified by HIV RNA (≤ or > 100 000 c/mL) at screening
Objective
- Non inferiority of DRV/r + 3TC at W48: % HIV RNA < 50 c/mL by intention
to treat, snapshot analysis
Baseline characteristics and patient disposition
Efficacy outcome at W48
Safety at W48
Back to Table of Contents
Download the slides
